Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.57 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 14/20 | 0.55 |
| ▸ | EGFR | P00533 | 12/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.53 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376058 | 0.82 | CSF1R (0.62) | PRMT5CSF1REGFR | |
| SCHEMBL5103910 | 0.78 | KDR (0.66) | PRMT5CSF1REGFR | |
| SCHEMBL4736127 | 0.77 | AURKA (0.60) | CHUKINSRMAPK8CAMKK2CSF1R | |
| SCHEMBL4814364 | 0.76 | PRMT5 (0.68) | PRMT5CSF1REGFR | |
| SCHEMBL4767171 | 0.76 | EGFR (0.77) | CSF1REGFR | |
| SCHEMBL27585232 | 0.76 | EGFR (0.77) | CSF1REGFR | |
| SCHEMBL5100203 | 0.75 | CSF1R (0.58) | PRMT5CSF1REGFR | |
| SCHEMBL4766838 | 0.75 | CSF1R (0.60) | CSF1REGFR | |
| SCHEMBL4769376 | 0.75 | BRAF (0.51) | CHUKINSRMAPK8CAMKK2CSF1R | |
| SCHEMBL4770875 | 0.75 | CSF1R (0.52) | CHUKINSRMAPK8CAMKK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | PRMT5 219/4885CHUK 866/4885INSR 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.